Cathay Biotech (SH:688065) Zheng Quan Zhi Xing·2025-08-15 14:10Core Viewpoint - The company has announced adjustments to the grant price of its 2022 restricted stock incentive plan and the cancellation of certain unvested restricted stocks, following the completion of its annual profit distribution plan [1][5][8]. Summary by Sections Decision Process and Disclosure - The company has followed the necessary decision-making procedures and disclosed relevant information regarding the 2022 restricted stock incentive plan, including independent opinions from the board of directors [1][2][3]. Adjustments and Results - The grant price for the 2022 restricted stock incentive plan has been adjusted from 56.45 yuan per share to 56.05 yuan per share due to the implementation of a cash dividend distribution of 4.00 yuan per 10 shares [5][6][8]. - The adjustment is in accordance with the regulations outlined in the "Management Measures for Equity Incentives of Listed Companies" and the 2022 incentive plan [5][8]. Cancellation of Restricted Stocks - A total of 69.881 million shares of unvested restricted stocks will be canceled due to the company not meeting the performance conditions required for vesting [7][8]. - The performance conditions included a minimum revenue growth rate of 186% for the first vesting period and 107% for the second vesting period, which were not achieved [6][7]. Impact on the Company - The adjustments to the grant price and the cancellation of unvested restricted stocks are not expected to have a significant impact on the company's financial status or operational stability [8]. Supervisory Board Opinion - The supervisory board has agreed that the adjustments to the grant price and the cancellation of unvested stocks comply with relevant laws and regulations, and do not harm the interests of the company or its shareholders [8][9].